Background-Ablation failure and recurrence rates after ventricular tachycardia (VT) ablation in nonischemic cardiomyopathy are high and the optimal procedural end point is not well defined. This study assessed the outcome after ablation, the impact of noninducibility, and other potential predictors of VT recurrence. Methods and Results-Forty-five patients with nonischemic cardiomyopathy (60±16 years; left ventricular ejection fraction, 44±14%) accepted for VT ablation were included. Epicardial mapping was performed in 29 (64%). A median of 2 (firstto-third quartile, 2-4) VTs (cycle length, 342±77 ms) were induced per patient. After ablation, the complete programmed electric stimulation protocol (3 drive cycle length, 3 extrastimuli ≥200 ms, and burst≥2 sites) was repeated. Complete success (noninducibility of any monomorphic VT) was achieved in 17 patients (38%), partial success (elimination of clinical VT, persistent inducibility of nonclinical VT) in 17 patients (38%), and failure (persistent inducibility of clinical VT) in 11 patients (24%). During 25±15 months of follow-up, VT occurred in 24 patients (53%), but the 6-month VT burden was reduced by ≥75% in 79%. Recurrence rates were low after complete procedural success (18%), but high after both partial success (77%) and failure (73%). Non-complete procedural success was the strongest predictor of VT recurrence (hazard ratio, 8.20; 95% confidence interval, 2.37-28.43; P=0.001). Conclusions-Although 53% of patients had VT during follow-up, the 6-month VT burden was decreased by ≥75% in 79%.
I n patients with left ventricular (LV) nonischemic cardiomyopathy (NICM), several aspects of ventricular tachycardia (VT) ablation require elucidation.
First, the procedural end point is not well defined. Although noninducibility of VT by programmed electric stimulation (PES) is frequently used as an end point, data supporting its predictive value for VT recurrence are mainly derived from patients after myocardial infarction (MI) 1,2 who are likely to have different substrates, higher procedural success, and lower VT recurrence rates. 1, 3 In addition, studies in post-MI patients are inconsistent, perhaps because of different induction protocols, incomplete application of protocols, and differences between patient populations. 1, 2, [4] [5] [6] Data on the value of PES as a procedural end point in NICM are limited to 2 small series. 3, 7 Recently, alternative end points have been proposed, such as elimination of abnormal bipolar electrograms or late potentials consistent with slow conduction 4, 8 ; late potentials are, however, less frequently found in patients with NICM than in post-MI patients. 3 Second, risk factors for VT recurrence in NICM are not established. Risk stratification may allow an individually tailored treatment strategy. A conservative approach may be appropriate in patients at low risk, whereas patients at high risk may require either more extensive ablation or concomitant drug therapy.
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Third, the role of VT ablation early in the therapeutic course (eg, for a first VT, symptomatic ATP, or a single implantable cardioverter defibrillator [ICD] shock) is unclear in NICM patients. The indication for VT ablation in patients with structural heart disease has changed over time. 9 Recent recommendations apply to all patients with structural heart disease, although evidence is limited and based on trials conducted in post-MI patients. 10, 11 The risk-benefit ratio of VT ablation early in the therapeutic course may be different in patients with NICM, in whom VT ablation is reported to be less effective 1, 3 and may more often require epicardial ablation, which is associated with higher procedural risks. 12, 13 The aims of the current study are (1) to determine the outcomes of VT ablation in NICM, (2) to assess the value of PES as a procedural end point, (3) to identify predictors of acute and long-term outcome, and (4) to evaluate the role of VT ablation early in the therapeutic course in NICM.
Methods

Patients
The study population consisted of 45 consecutive NICM patients who underwent VT ablation at the Leiden University Medical Center between January 2007 and June 2011, including patients in whom no radiofrequency (RF) energy was delivered. All patients had systolic impairment and evidence of scar in the LV based on contrast-enhanced MRI and/or electroanatomical mapping. Patients with significant coronary artery disease (>50% stenosis, assessed by coronary angiography in all patients), congenital heart disease, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, LV noncompaction, restrictive cardiomyopathy, (sub)acute myocarditis, cardiac sarcoidosis, toxic cardiomyopathy, tachycardia-induced cardiomyopathy, or primary valvular abnormalities were excluded. All patients were treated according to the routine clinical protocol and provided informed consent.
Clinical Presentation and Procedural Strategy
In patients presenting with incessant VT, ≥2 ICD shocks, or multiple VT recurrences after prior endocardial ablation, VT ablation was classified as late in the therapeutic course. In these patients, epicardial mapping was always attempted if endocardial ablation did not result in complete success. In patients presenting with a first VT, symptomatic ATP, or a single ICD shock, VT ablation was classified as early in the therapeutic course. In these patients, epicardial mapping was not attempted in case of (1) prior surgery, (2) a septal or basal anterior substrate likely not reachable from the epicardium because of coronary arteries and a basal fat layer, (3) only remaining nonclinical very fast VT (cycle length [CL] ≤250 ms), and (4) patient preference.
VT Induction
The procedure was performed under conscious sedation (n=43) or general anesthesia (n=2); antiarrhythmic drugs (AADs) were discontinued for ≥5 half-lives with the exception of amiodarone (n=19; 42%). In patients who were not under general anesthesia, PES was performed before sedation and opioid administration. PES consisted of 3 drive CLs (600, 500, and 400 ms) with 3 ventricular extrastimuli (≥200 ms) from ≥2 right ventricular sites and burst pacing. Positive end point was induction of sustained monomorphic VT lasting >30 seconds or requiring termination because of hemodynamic compromise. Isoprenaline was used if the (presumptive) clinical VT could not be induced. Induced VTs were regarded clinical if the 12-lead ECG matched that of a spontaneous VT, or presumptive clinical when the CL matched that of an ICD-recorded VT (difference <30 ms).
Electroanatomical Mapping and Ablation
Electroanatomical LV endocardial mapping was performed retrogradely during pacing or sinus rhythm using a 3.5-mm, irrigatedtip catheter and an electroanatomical mapping system (NaviStar ThermoCool and CARTO XP, Biosense Webster Inc, Diamond Bar, CA). Epicardial mapping was performed through a subxiphoid puncture. Electrograms were filtered at 30 to 400 Hz (bipolar) and 1 to 240 Hz (unipolar). Endocardial areas with low bipolar voltage (≤1.50 mV) or low unipolar voltage (≤8.27 mV) 14 and epicardial areas with low bipolar voltage (≤1.81 mV) 15 and low unipolar voltage areas (≤7.95 mV) 15 were considered abnormal and consistent with scar if ≥1 cm 2 in size and accompanied by double potentials, fragmented electrograms, late potentials, or other prolonged electrograms ≥50 ms. 15 Substrates were classified as septal if they were predominantly located in one of the anteroseptal or inferoseptal segments. Endocardial and epicardial ablation target sites were identified based on the combination of substrate, pace, activation, and entrainment mapping for stable VT, and based on substrate and pace mapping for unstable VT (defined as VTs requiring prompt termination). 9 At the epicardium, ablation was usually withheld when the estimated distance to a coronary artery was <5 mm, as assessed by integrated CT-derived coronary anatomy and coronary angiography. 16 High output pacing (10 mA, 2 ms) was performed to determine the location of the phrenic nerve. RF energy was applied at 30 to 45 W (maximum temperature, 45ºC; flow, 20-30 mL/min; 60 s) for endocardial sites and ≤50 W (flow 20 mL/min) for epicardial sites.
Acute Procedural Outcome and Reasons for Noncomplete Procedural Success
After the last RF application, the entire PES protocol was repeated in each patient. Isoprenaline was administered if required to induce VT before ablation. Complete procedural success was defined as noninducibility of any sustained monomorphic VT regardless of VT CL; partial success as elimination of the (presumptive) clinical VT but persistent inducibility of ≥1 nonclinical VT; and failure as persistent inducibility of the (presumptive) clinical VT.
Reasons for non-complete procedural success (partial success and failure) were categorized as (1) vicinity of coronary arteries and/or epicardial fat, (2) proximity of the His bundle, (3) pericardial adhesions, (4) prolonged low cardiac output after electric cardioversion, (5) no identifiable target site for fast clinical VT, (6) multiple cardioversions for nonclinical fast VT with hemodynamic collapse, and (7) patient preference for medical therapy.
Follow-up
ICDs were offered to all patients regardless of acute procedural outcome. ICDs were typically programmed to include 3 zones: monitor zone (150-188 beats per minute; ATP if indicated), fast VT zone (188-210 beats per minute; ATP and shock), and ventricular fibrillation zone (>210 beats per minute; if available ATP during charging, and shock). Patients were followed up at 3, 6, and 12 months after ablation and at 6 to 12 monthly intervals thereafter. Recordings were analyzed by 2 experienced observers. Recurrence was defined as any VT treated with ATP or shock and any sustained VT occurring in the monitor zone, including VTs that occurred before discharge from the hospital. In patients without an ICD, VT recurrence was defined as sustained VT documented on a 24-hour Holter ECG or any complaints suggestive for VT. The reduction of VT burden was calculated as follows: 1-(no. of VT episodes in period post ablation/no. of VT episodes in same period pre-ablation).
Disease Progression
To analyze the effect of disease progression on VT recurrence, the LV end-diastolic volume (LVEDV) and LV ejection fraction (LVEF) were assessed by transthoracic echocardiography before the procedure and during follow-up. The annual changes in LVEDV and LVEF were calculated as follows: (value last echocardiogram-value baseline echocardiogram)/time interval in years.
Statistical Analysis
Categorical variables are displayed as number (percentage) and continuous variables are expressed as mean±SD when normally distributed or median (first-to-third quartile [Q1-to-Q3]) when nonnormally distributed. Categorical variables were compared using the χ 2 test or the Fisher exact test when the expected value in any cell was <5. Continuous variables were compared using the Student t test when normally distributed or the Mann-Whitney U test when non-normally distributed. The VT burden before and after ablation was compared using the Wilcoxon signed rank test. Survival curves were estimated by the Kaplan-Meier method and compared by the log-rank test. Univariable logistic regression and Cox regression analysis were performed to identify predictors of acute procedural success and predictors of VT recurrence, respectively. Start of cardiac resynchronization therapy during follow-up was included as a timedependent covariate. Multivariable analyses were not performed because of the limited number of patients and events. P values are all 2-sided and, if not otherwise specified, a P value <0.05 was considered statistically significant. Analyses were performed using SPSS 20.0 software (SPSS Inc, Chicago, IL).
Results
Patients
Forty-five consecutive patients with NICM (76% men; age, 60±16 years) were included after failure of 1.8±1.0 AADs. Twelve patients (27%) had previously undergone endocardial VT ablation, 2 of them at another center. Baseline characteristics are displayed in Table 1 and the procedural strategy in Figure 1 .
Procedure
A median of 2 (Q1-to-Q3, 2-4) VTs with a mean CL of 342±77 ms was induced per patient. Clinical VTs (mean CL, 363±98 ms) were induced in 43 patients (96%) and only nonclinical VT in 2 patients (4%), which was based on the 12-lead ECG in 36 patients (80%) and on ICD recordings in 9 patients (20%). In only 1 patient isoprenaline administration was required to induce the clinical VT before ablation (2%). Bundle branch reentry VT was induced in 3 patients (7%).
Endocardial mapping was performed in all patients, percutaneous epicardial mapping in 29 patients (64%), and intraoperative epicardial mapping in 2 patients (4%, in 1 both percutaneous and intraoperative). Abnormal low bipolar or low unipolar voltage areas were present in all patients who underwent both endocardial and epicardial substrate mapping. Neither RF catheter ablation nor intraoperative cryoablation was performed in 2 patients (4%) because no target site could be identified. Procedural data are summarized in Table 2 . 
Acute Procedural Outcome and Reasons for Non-complete Success
Complete success was achieved in 17 patients (38%), partial success in 17 (38%), and failure in 11 (24%, including the 2 patients in whom neither RF nor cryoablation was performed). In 2 patients the clinical VT was abolished but the final induction protocol could not be completed because of prolonged low cardiac output after nonclinical VT induction; partial success was achieved in both.
The reasons for non-complete procedural success were proximity of coronary arteries and/or epicardial fat in 5 (18%), the proximity of the His bundle in 2 (7%), adhesions because of prior surgery in 1 (4%), prolonged low cardiac output after cardioversion in 2 (7%), no identifiable target site for fast clinical VT in 5 (18%), multiple cardioversions because of nonclinical fast VT with hemodynamic collapse in 11 (39%), and patient preference for medical therapy in 2 patients (7%).
Seven patients did not undergo epicardial mapping, despite non-complete procedural success, because of prior surgery in 1, a basal septal substrate likely not reachable from the epicardium based on contrast-enhanced MRI in 1, patient preference in 1, and only remaining very fast nonclinical VT in the setting of ablation early in the therapeutic course in 4 patients.
Predictors of Acute Procedural Outcome
A higher age (odds ratio, 1.78; P=0.01) and lower creatinine clearance (odds ratio, 1.28 per 10 mL/min decrease; P=0.03) were associated with non-complete procedural success (Figure 2) . A trend was observed for lower LVEF (odds ratio, 1.52 per 10% decrease; P=0.09) and induction of unstable VT (odds ratio, 3.26; P=0.08).
Complications
One patient developed a pseudoaneurysm of the femoral artery. Acute pericardial bleeding >80 mL occurred in 2 of 29 patients (7%) who underwent pericardial puncture. One patient (3%) who accidentally received heparin developed tamponade after the procedure managed by drainage.
VT Recurrence During Follow-up
All but 4 patients were discharged with an ICD; 8 patients (18%) were discharged on class I AADs, 29 (64%) on β-blocker, 10 (22%) on sotalol, and 17 (38%) on amiodarone. During a median follow-up of 24 (Q1-to-Q3, 12-37) months (no patient lost to follow-up; ≥6-month follow-up in 42 patients, remaining 3 patients died within 6 months), 24 patients (53%) had VT recurrence, 20 (44%) received ≥1 ICD shock, and 6 patients (13%) experienced an episode of electrical storm (defined as ≥3 appropriate ICD shocks within 24 hours). Only 1 of 8 patients with electrical storm before ablation had electrical storm recurrence.
The 6-month VT burden was reduced by ≥75% in 33 of 42 patients (79%) with ≥6-month follow-up ( Figure 3 ). The 6-month VT burden was reduced equally in patients with and without an ICD before ablation (78% versus 80% of patients ≥75% reduction; P>0.05). The 12-month VT burden was reduced by ≥75% in 68%, 78%, and 71% of patients in the first, second, and third year after ablation, respectively.
Eleven of 24 patients (46%) with VT recurrence had ≥1 fast VT (CL≤300 ms), and 20 of 24 patients (83%) with VT recurrence received ≥1 appropriate ICD shock. A median of 23% (Q1-to-Q3, 5%-64%) of all VTs per patient required a shock for termination.
Impact of Noninducibility
Only 3 of 17 patients (18%) with complete procedural success had VT recurrence, compared with 13 of 17 patients (77%) with partial procedural success and 8 of 11 patients (73%) with procedural failure (Figure 4 ). The 6-month VT burden was reduced by ≥75% in 94%, 67%, and 70%, respectively. Importantly, 6 of 11 patients (55%) with induction of a very fast VT (CL≤250 ms) at the end of the procedure had VT recurrence, including 2 of 3 patients 
Predictors of VT Recurrence
Disease Progression and VT Recurrence
Disease progression was assessed by repeat echocardiography ≤19±9 months after baseline echocardiography in the 21 of 42 patients (50%) with ≥6-month follow-up. The LVEF decreased by a median of 1.4% (Q1-to-Q3, −3.0% to 4.5%) and the LVEDV increased by a median of 10 mL (Q1-to-Q3, −10 to 26 mL) per year. In 5 patients (24%) the LVEF decreased by ≥5%/y, all had VT recurrence (100%). In 11 patients (31%) the LVEDV increased by ≥10 mL/y, 7 had VT recurrence (64%).
VT Ablation Early in the Therapeutic Course
Epicardial mapping was performed in 12 of 25 patients (48%; Figure 1 ) who underwent VT ablation early in the therapeutic course (ie, for a first VT, symptomatic ATP, or a single ICD shock). Complete success was achieved in 11 (44%), partial success in 8 (32%), and ablation failed in 6 (24%). The procedure was complicated by a pseudoaneurysm of the femoral artery in 1 patient (4%) and tamponade after the procedure in another (4%). During a median follow-up of 24 months (Q1-to-Q3, 13-37 months), 14 patients (56%) were free from VT and 15 (60%) were free from appropriate ICD shocks. Twelve of 25 patients (48%) were both off amiodarone and without recurrent VT during follow-up. The acute success rate and VT recurrence rate were not significantly different between patients undergoing ablation early in the therapeutic course and the other patients (P=0.58 and P=0.17; Figure 1 ).
Repeat Ablation
Repeat VT ablation was performed in 8 of 45 patients (18%) 11±11 months after the index procedure because of incessant VT and/or ≥1 appropriate ICD shock. Seven had prior partial success and 1 complete success. Pericardial puncture was performed in 4 (50%), but was unsuccessful because of adhesions in 2 patients who underwent epicardial mapping at baseline, despite intravenous steroids after the procedure. Complete procedural success was achieved in 3 of 8 patients (38%), partial success in 4 (50%), and failure in 1 (13%). During a mean follow-up of 17±13 months, 4 patients (50%) had VT recurrence and 2 (25%) received 1 appropriate ICD shock. Three of 6 patients (50%) with ≥6-month follow-up had ≥75% reduction of the 6-month VT burden.
Mortality During Follow-up
Six patients (13%) died during follow-up. The cause of death was terminal heart failure (n=2), incessant VT in the setting of progressive heart failure (n=2), respiratory insufficiency after cardiac surgery (n=1), and cancer (n=1). Two patients (4%) underwent cardiac transplantation.
Discussion
The main findings of this study can be summarized as follows: (1) although VT occurs in 53% of NICM patients after ablation, the 6-month VT burden was substantially reduced in 79%; (2) complete procedural success, defined as noninducibility of any VT after the last RF application, was associated with low VT recurrence rates, whereas partial success and procedural failure were both associated with high recurrence rates; (3) non-complete procedural success, a lower LVEF, a higher number of clinical VTs, VT storm, a higher number of failed AADs, and a higher mean CL of induced VTs are predictors of VT recurrence; and (4) after VT ablation early in the therapeutic course, 56% of NICM patients remain free from VT recurrence.
Prior Reports
To our knowledge, this series of NICM patients undergoing VT ablation and complete PES after the last RF delivery is the largest reported to date. Patients had a higher LVEF than patients in prior studies (44% versus 27%-34%) 3, 7, 13, [17] [18] [19] [20] , had less frequently an ICD before ablation (67% versus 71%-100%), 3, 7, 13, [17] [18] [19] [20] and were less often on amiodarone (42% versus 43%-88%) 3, 13, [17] [18] [19] [20] , suggesting that VT ablation was used at an earlier stage, which is in line with recently extended indications for VT ablation. 9 Complete procedural success was achieved in 38% of patients, which is lower than some prior studies 7,17,18 but similar to others. 3, 13, 21 However, the currently reported recurrence rate of 53% during a median follow-up of 24 (Q1-to-Q3, 12-37) months is, considering differences in follow-up duration, favorable when compared with 2 studies using epicardial mapping in the majority of patients 3, 13 and similar to 1 study with epicardial mapping in all patients. 17 An overview of studies analyzing outcome of VT ablation in NICM is provided in the Table in the online-only Data Supplement.
Noninducibility as a Procedural End Point
The majority of available data on the predictive value of noninducibility is derived from post-MI patients. 1,2,4-6 NICM patients may, however, have a different arrhythmogenic substrate. 3, 22 Of interest, 96% of our patients were inducible for the clinical VT, suggesting the presence of a fixed substrate. The small number of patients under general anesthesia and the fact that initial PES was performed before sedative and opioid administration may also have contributed to this finding.
Only 2 small prior studies (including 13 and 16 patients) have analyzed the value of PES at the end of VT ablation procedures in patients with NICM. 3, 7 In the present study, PES was performed after the last RF application in all 45 patients. Perhaps because of the consistent application of the induction protocol, patients remained more often inducible for nonclinical and, in particular, fast VTs, and, therefore, partial success may have been achieved more frequently compared with prior studies (Table in the online-only Data Supplement). Prolonged depression of cardiac output prevented completion of the induction protocol in only 2 patients, which may be partly because of the higher LVEF and our strategy to perform substrate mapping and only limited mapping during VT in all patients independent of VT CL.
Both partial procedural success and failure were associated with high VT recurrence rates, indicating that partial success may not be superior to ablation failure. Importantly, 55% of patients with induction of a very fast VT (CL≤250 ms) after ablation had VT recurrence, suggesting that induction of these VTs after ablation is not a nonspecific finding. However, the latter does not necessarily imply that very fast, nonclinical VTs should always be targeted. Persistent inducibility of very fast VTs may be a marker for a more complex or functional arrhythmogenic substrate less amenable to VT ablation. This is in line with the observation that 83% of patients required ≥1 ICD shocks to terminate ≥1 VT, which may be because of ATP failure or short VT CL. Further studies are needed to assess whether additional ablation can abolish these nonclinical, usually rapid VTs and improve long-term outcomes after ablation.
Predictors of Acute Procedural Success and VT Recurrence
Higher age was strongly associated with non-complete procedural success, also after adjustment for epicardial access, LVEF, and AADs (data not shown), perhaps because of a different substrate in older patients. Interestingly, although age was associated with non-complete procedural success, it seemed not to predict VT recurrence. All patients with a significantly decreasing LVEF and 64% of patients with a significantly increasing LVEDV had VT recurrence during follow-up, perhaps indicating that patients with deteriorating LV function and dimensions may be at high risk for VT recurrence. Previous studies in post-MI patients demonstrated that a lower LVEF, 6,23 a higher number of induced VTs, 23,24 a higher number of clinical VTs, 6 and acute procedural failure 6 are associated with VT recurrence. The current study suggests that most of these factors also apply to patients with NICM. Different substrates may, however, result in comparable clinical features, such as lower LVEF, and to date little is known about the VT substrates in NICM. Therefore, more studies are needed to identify potentially different substrates and their impact on VT occurrence. So far, PES after the last RF application is the strongest predictor of VT recurrence and may, therefore, be an important tool to identify patients who may need additional ablation, epicardial mapping, and/or enhanced drug therapy.
VT Ablation Early in the Therapeutic Course
This is the first study reporting on the results of VT ablation in NICM patients presenting with a first VT, symptomatic ATP, or a single ICD shock. Importantly, no complication resulted in serious sequelae. Fifty-six percent had no VT recurrence and 60% were free from ICD shocks during follow-up. Twelve of 25 patients (48%) were off amiodarone and without recurrent VT during follow-up. These findings suggest that VT ablation may be considered for indications, such as a first VT, symptomatic ATP, or a single ICD shock in NICM patients and perhaps even be considered as an alternative to life-long amiodarone therapy, particularly in young patients.
The risks of VT ablation should be weighed carefully against the risks of medical therapy, which persist during follow-up and may include serious side effects. When considering epicardial ablation, the risk of pericardial adhesions preventing future pericardial access should also be taken into account, which may occur even after administration of intrapericardial steroids.
